Blueprint medicines corporation (BPMC)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Revenues:
Total revenues

66,512

44,521

21,426

27,772

11,400

-

-

Cost and operating expenses
Research and development

331,450

243,621

144,687

81,131

48,588

31,844

15,928

Selling, general and administrative

96,388

47,928

27,986

19,218

14,456

7,890

5,072

Total cost and operating expenses

427,838

291,549

172,673

100,349

63,044

39,734

21,000

Other income (expense):
Interest income (expense), net

13,732

10,566

3,204

469

696

453

138

Other income (expense), net

-100

-180

-76

551

-429

-98

226

Total other income

13,632

10,386

3,128

82

-1,125

-551

88

Net loss

-347,694

-236,642

-148,119

-72,495

-52,769

-40,285

-20,912

Other comprehensive loss:
Unrealized gain (losses) on pension benefit obligations

-2,985

-

-

-

-

-

-

Unrealized gain (losses) on available-for-sale investments

671

105

-251

-18

-

-

-

Currency translation adjustments

-40

-16

-

-

-

-

-

Comprehensive loss

-350,048

-236,553

-148,370

-72,513

-52,769

-40,285

-

Net loss per share - basic and diluted

-7.27

-5.39

-3.92

-2.64

-

-

-

Reconciliation of net loss applicable to common stockholders:
Net loss

-347,694

-236,642

-148,119

-72,495

-52,769

-40,285

-20,912

Convertible preferred stock dividends

-

-

-

-

3,153

5,765

2,870

Net loss applicable to common stockholders

-

-

-

-

-55,922

-46,050

-23,782

Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)

-

-

-

-

-3.07

-32.41

-23.43

Weighted-average number of common shares used in net loss per share - basic and diluted

47,829

43,867

37,793

27,492

18,236

1,421

1,015